WHC is still in active development. Read this to understand our approach.
depiction of HCFDWZZGGLSKEP-UHFFFAOYSA-N.svg
tripsit

doxylamine

Verificar en tripsit

psychonaut

Doxylamine

Verificar en psychonaut

pubchem

Doxylamine

Verificar en pubchem

drugmap

Doxylamine

Verificar en drugmap

wiki

Doxylamine

Verificar en wiki

Data

InChI: InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3

Sinónimos: BRD-A44008656-036-05-0,Spectrum_001014, Doxylamine (INN),GTPL7171,NCGC00021147-03,R-Doxylamine,CCG-204443,2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine,KBio1_000841,KBio2_004062,NCGC00089789-05,NCGC00021147-21,469-21-6,Lopac0_000348,FT-0603401,N,N-dimethyl-2-(1-phenyl-1-(pyridin-2-yl)ethoxy)ethanamine,Doxilminio [INN-Spanish],NCGC00021147-09,KBioSS_001494,Spectrum2_000115,DB00366, Dormidina (TN), 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine,DivK1c_000841,AB00053466,Pyridine, 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)-,AC-15949,Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether,N,N-Dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine #, N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine,BSPBio_000093,UNII-95QB77JKPL,Prestwick3_000027,2-(.ALPHA.(2-(DIMETHYLAMINO)ETHOXY)-.ALPHA.-METHYLBENZYL)PYRIDINE,KBio2_006630,N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine,EC 207-414-2,(+/-)-Doxylamine, Dossilamina [DCIT],469D216,STL018676,doxylamine, Doxylaminum,Doxylamine [INN:BAN],KBioGR_001135, Doxilminio,BPBio1_000103, N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine, Dolased (TN),Doxilminio,NCGC00021147-13,2-(.alpha.-(2-(Dimethylamino)ethoxy)-.alpha.-methylbenzyl)pyridine,2-Dimethylaminoethoxyphenylmethyl-2-picoline,HMS3604L05,Phenyl-2-pyridylmethyl-.beta.-N,N-dimethylaminoethyl ether, Diclectin (TN),L001076,NCGC00021147-08,Decapryn (TN), Donormyl (TN), Unisom-2 (TN),NCGC00021147-05, N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine,NCGC00021147-04,Doxylaminum [INN-Latin],Mereprine, Dozile (TN),Ethanamine, N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]-, Evanorm (TN),KBio2_001494, Doxilamina, N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine,Doxylamine (INN),Spectrum4_000528,Prestwick1_000027,AB00053466-18,Dossilamina,Doxylamine,N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine,IDI1_000841,CHEBI:51380,Gittalun,D07878,AB00053466_20, Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether, Doxylamine [INN:BAN],BRD-A44008656-036-15-9,NCI C60684,N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine, Doxilminio [INN-Spanish],Spectrum3_000409,DOXYLAMINE [MI],Alsadorm,N,N-Dimethyl-2-(1-phenyl-1-pyridin-2-yl-ethoxy)ethanamine,Q423390,DB-051407,DOXYLAMINE [WHO-DD],AB00053466_19,EINECS 207-414-2,SDCCGSBI-0050336.P005,PYRIDINE, 2-(.ALPHA.-(2-(DIMETHYLAMINO)ETHOXY)-.ALPHA.-METHYLBENZYL)-, Syndol (TN),Sedaplus, Mersyndol (TN), Restavit (TN),NCGC00089789-04,DOXYLAMINE [INN],AKOS005657227,CHEMBL1004,BSPBio_001938,NCGC00021147-06, Somnil (TN),95QB77JKPL,Prestwick2_000027,Pyridine, 2-[.alpha.-[2-(dimethylamino)ethoxy]-.alpha.-methylbenzyl]-,Hoggar,DOXYLAMINE [HSDB],5-21-03-00508 (Beilstein Handbook Reference),SPBio_002014,Ethanamine, N,N-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)-,NCGC00021147-02,KBio3_001158,N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine,Z2242151271,dimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine,doxilamina,SCHEMBL4709,Dossilamina [DCIT],SPBio_000130,Spectrum5_000949, 2-Dimethylaminoethoxyphenylmethyl-2-picoline,.alpha.-Dimethylaminoethoxyphenylmethyl-2-picoline,EN300-123421,Doxylaminum,DOXYLAMINE [VANDF],N,N-dimethyl-2-(1-phenyl-1-(pyridin-2-yl)ethoxy)ethan-1-amine,BRN 0230379,DTXSID1022970,Prestwick0_000027,HSDB 5184,NCGC00089789-02,BCP09058,SBI-0050336.P004,NINDS_000841, Doxylaminum [INN-Latin]

Estimated data

Solubilidad: -2.416 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 44.1% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.